NCT03384238 2026-03-17
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Stanford University
Phase 1/2 Recruiting
Clinical Trials
13 trialsNCT05973331 2026-02-09
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
Beth Israel Deaconess Medical Center
Active not recruiting
NCT02336087 2026-02-04
Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery
City of Hope Medical Center
Phase 1 Active not recruiting
NCT06760234 2026-01-07
Multimodal Deep Learning Model Predicts Pancreatic Cancer Prognosis
Second Affiliated Hospital, School of Medicine, Zhejiang University
Completed
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT05077800 2025-11-18
FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03404960 2025-10-10
Parpvax
University of Pennsylvania
Phase 1/2 Completed
NCT03245541 2025-10-07
Radiation Therapy in Combination With Durvalumab for People With Pancreatic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT06149689 2025-08-07
PTCA199-7
Fudan University
Phase 2 Recruiting
NCT06250972 2025-08-07
PTCA199-11
Fudan University
Phase 3 Recruiting
NCT05624918 2025-07-31
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT04992507 2025-07-10
Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT05287347 2025-05-25
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
Beth Israel Deaconess Medical Center
Withdrawn